Search for a trial

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone & in
Combination with Nivolumab in Advanced Solid Tumors

Primary Objectives: - To characterize the safety, tolerability, and DLTs and to determine the MTD/RP2D of BMS-986218 administered as monotherapy and in combination with nivolumab in participants with advanced solid tumors- To evaluate the efficacy…

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA

This study has been transitioned to CTIS with ID 2024-513519-28-00 check the CTIS register for the current data. Primary objective • To compare the event-free survival (EFS) of neoadjuvant ipilimumab + nivolumab (followed by adjuvant nivolumab or…

Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)

This study has been transitioned to CTIS with ID 2024-515514-40-00 check the CTIS register for the current data. The primary objective is to investigate the rate of pathological responses following different neoadjuvant immunotherapy combinations in…

rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT)

To determine the real-world pharmacokinetics of ICIs.

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab
Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma
Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Primary ObjectivePart A: To compare disease-free survival (DFS) per Blinded Independent Central Review (BICR) of nivolumab combined with ipilimumab versus placebo infusions in participants with localized RCC, with a predominantly clear cell…

Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer. The NICHE trial.

This study has been transitioned to CTIS with ID 2024-513314-35-00 check the CTIS register for the current data. Primary Objective: To determine the safety and feasibility of pre-operative immunotherapy in CRC. Additional Primary Objective for the…

A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated Unresectable or Metastatic Melanoma

Primary Objectives - To compare Overall Survival (OS) and Progression free survival (PFS) of nivolumab monotherapy to ipilimumab monotherapy and that of nivolumab combined with ipilimumab to ipilimumab monotherapy in subjects with previously…

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma

In this randomized controlled phase III study we will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression free survival when randomly compared…

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

This study has been transitioned to CTIS with ID 2024-516938-34-00 check the CTIS register for the current data. The primary objective of this study is to evaluate the rate of ongoing response at 12 months after start of treatment in patients with…

Evaluating the safety of shortened infusion times for different oncological immunotherapies; An observational prospective study

This study has been transitioned to CTIS with ID 2024-518878-14-01 check the CTIS register for the current data. Primary ObjectiveTo determine the incidence and grading of infusion related/hypersensitivity reactions reported per drug using the…

A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in
Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in
Participants with Microsatellite Instability High (MSI-H) or Mismatch
Repair Deficient (dMMR) Metastatic Colorectal Cancer

This study has been transitioned to CTIS with ID 2023-503956-29-00 check the CTIS register for the current data. Primary Objective:All lines1) To compare the BICR-assessed PFS of participants with centrally confirmed dMMR/MSI-H mCRC and randomized…

18F-PD-L1 PET/CT to predict response to nivolumab in patients with NSCLC

• To assess the relation between 18F-PD-L1 PET/CT outcome measures and progression-free survival of >=9 months according to RECIST 1.1.• To assess the relation between 18F-PD-L1 PET/CT outcome measures and patient outcome in terms of PFS and…

Multicenter Phase 1b trial testing the Neoadjuvant Combination of Domatinostat, Nivolumab, and Ipilimumab, in IFN-gamma signature-low and IFN-gamma signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma -DONIMI.

Primary objectives: - To assess safety and feasibility of neoadjuvant nivolumab +/- domatinostat +/- ipilimumab- To identify pathologic response rates of nivolumab +/- domatinostat +/- ipilimumabSecondary objectives: - To describe all grade…

Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)

This study has been transitioned to CTIS with ID 2024-515080-54-00 check the CTIS register for the current data. Primary objectiveTo determine the pathological complete response rate per cohort

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

This study has been transitioned to CTIS with ID 2022-501784-40-00 check the CTIS register for the current data. The study aims to demonstrate that treatment with nivolumab combined with ipilimumab will improve efficacy in cisplatin-ineligible…

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

This study has been transitioned to CTIS with ID 2023-504761-23-00 check the CTIS register for the current data. The co-primary endpoints of this study are PFS in intermediate and poor-risk subjects, as assessed by an Independent Radiology Review…

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in
Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)

The objective of this study is to investigate the safety and effectiveness of different combinations of cancer immunotherapies compared to either Nivolumab or Ipilimumab, as determined by comparing the Overall Response Rate, at 24 weeks in patients…

An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)

Primary objectives - To evalulate the association between baseline tissue TMB/blood TMB and clinical efficacy (Objective Response Rate) for participants in Part 2- To evaluate the correlation between baseline tissue TMB and blood TMB for…

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA (MORPHEUS-MELANOMA)

• To evaluate the efficacy of treatment• To evaluate the safety of treatment

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus standard of care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma

Primary Objectives• To compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to standard of care in patients with previously untreated and advanced non-clear cell RCC, Secondary Objectives• To compare the OS rate at 6 and 18…